BRPI0414365A - composições, reagentes e kits para, e métodos de diagnosticar, monitorar e tratar obesidade e/ou diabetes - Google Patents

composições, reagentes e kits para, e métodos de diagnosticar, monitorar e tratar obesidade e/ou diabetes

Info

Publication number
BRPI0414365A
BRPI0414365A BRPI0414365-5A BRPI0414365A BRPI0414365A BR PI0414365 A BRPI0414365 A BR PI0414365A BR PI0414365 A BRPI0414365 A BR PI0414365A BR PI0414365 A BRPI0414365 A BR PI0414365A
Authority
BR
Brazil
Prior art keywords
diabetes
diagnosing
kits
reagents
compositions
Prior art date
Application number
BRPI0414365-5A
Other languages
English (en)
Inventor
Liat Mintz
Original Assignee
Liat Mintz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liat Mintz filed Critical Liat Mintz
Publication of BRPI0414365A publication Critical patent/BRPI0414365A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6879—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for sex determination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01146—11-Beta-hydroxysteroid dehydrogenase (1.1.1.146)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

"COMPOSIçõES, REAGENTES E KITS PARA, E MéTODOS DE DIAGNOSTICAR, MONITORAR E TRATAR OBESIDADE E/OU DIABETES". A presente invenção refere-se a treze novas variantes de divisão alternativa dos genes relacionados com a obesidade e/ou diabetes.
BRPI0414365-5A 2003-09-11 2004-09-09 composições, reagentes e kits para, e métodos de diagnosticar, monitorar e tratar obesidade e/ou diabetes BRPI0414365A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/659,782 US7176292B2 (en) 2003-09-11 2003-09-11 Ghrelin variant protein
PCT/US2004/029230 WO2005026392A2 (en) 2003-09-11 2004-09-09 Compositions, reagents and kits for and methods of diagnosing, monitoring and treating obesity and/or diabetes

Publications (1)

Publication Number Publication Date
BRPI0414365A true BRPI0414365A (pt) 2006-11-14

Family

ID=34273528

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414365-5A BRPI0414365A (pt) 2003-09-11 2004-09-09 composições, reagentes e kits para, e métodos de diagnosticar, monitorar e tratar obesidade e/ou diabetes

Country Status (14)

Country Link
US (2) US7176292B2 (pt)
EP (1) EP1664346B1 (pt)
JP (2) JP2007504825A (pt)
KR (1) KR101081040B1 (pt)
CN (1) CN101023184A (pt)
AT (1) ATE480641T1 (pt)
AU (2) AU2004273053B2 (pt)
BR (1) BRPI0414365A (pt)
CA (1) CA2538514C (pt)
DE (1) DE602004029061D1 (pt)
IL (2) IL174195A (pt)
NZ (1) NZ546488A (pt)
RU (1) RU2420583C2 (pt)
WO (1) WO2005026392A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8512971B2 (en) * 2002-12-10 2013-08-20 Echelon Biosciences, Inc. Compounds and methods of use thereof for assaying lysophospholipase D activity
US20050208658A1 (en) * 2003-11-21 2005-09-22 The University Of Maryland RNA interference mediated inhibition of 11beta hydroxysteriod dehydrogenase-1 (11beta HSD-1) gene expression
EP1747264B1 (de) 2004-05-21 2012-09-12 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Multizelluläre gewebe- und organkultursysteme
WO2005119525A1 (en) * 2004-06-04 2005-12-15 Pfizer Products Inc. 11βHSD1 CRYSTAL STRUCTURES FOR STRUCTURE BASED DRUG DESIGN
JP2009514548A (ja) * 2005-11-03 2009-04-09 リアット・ミンツ ホルモン不均衡を診断、モニターおよび治療するため組成物、試薬およびキットおよびその方法
US7981860B2 (en) * 2006-03-13 2011-07-19 Liat Mintz Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite-stimulation
US7763707B2 (en) * 2006-03-13 2010-07-27 Liat Mintz Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite-stimulation
WO2007126792A2 (en) * 2006-03-28 2007-11-08 Liat Mintz Use of ghrelin splice variant for treating high cholesterol levels or high plasma glucose levels and releated diseases
WO2009048903A1 (en) * 2007-10-08 2009-04-16 Bristol-Myers Squibb Company 11 beta hydroxysteroid dehydrogenase type 1
JP2011516038A (ja) * 2008-03-12 2011-05-26 オタゴ イノベーション リミテッド バイオマーカー
ES2372337B1 (es) * 2010-06-10 2013-01-18 Servicio Andaluz De Salud Variante de la ghrelina y sus usos.
WO2013113916A2 (en) * 2012-02-03 2013-08-08 Zealand Pharma A/S Ghrelin analogues
CN102721819B (zh) * 2012-06-28 2014-08-13 广州瑞博奥生物科技有限公司 一种脂联素的竞争抑制性酶联免疫检测试剂盒及方法
WO2017018735A1 (ko) * 2015-07-24 2017-02-02 고려대학교 산학협력단 노화 판별용, 비만 판별용, 암 진단용 바이오마커 및 이를 이용한 진단키트

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291653B1 (en) * 1997-03-24 2001-09-18 Zymogenetics, Inc. Antibodies to motilin homologs
US20040023874A1 (en) * 2002-03-15 2004-02-05 Burgess Catherine E. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US6967237B2 (en) * 2000-05-30 2005-11-22 Merck & Co., Inc. Ghrelin analogs
CA2459489C (en) * 2001-08-17 2010-02-02 Rebio Gen, Inc. Method for diagnosing or monitoring carbohydrate metabolism disorders
EP1458758A2 (en) * 2001-12-21 2004-09-22 Maxygen Aps Adiponectin fragments and conjugates
EP1463752A4 (en) * 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUM INFUSION PROTEINS
PT1463751E (pt) * 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
EP1474445A4 (en) * 2002-01-18 2007-02-21 Protemix Corp Ltd ADIPONECTIN GLYCO-ISOFORMS, AND USES THEREOF
US20060199761A1 (en) * 2002-01-31 2006-09-07 Japan Science And Technology Agency Insulin resistance improving agent
US7981860B2 (en) * 2006-03-13 2011-07-19 Liat Mintz Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite-stimulation

Also Published As

Publication number Publication date
DE602004029061D1 (de) 2010-10-21
WO2005026392A2 (en) 2005-03-24
EP1664346B1 (en) 2010-09-08
US7176292B2 (en) 2007-02-13
RU2006111720A (ru) 2007-10-20
CA2538514C (en) 2014-04-08
JP2011182776A (ja) 2011-09-22
JP5314658B2 (ja) 2013-10-16
AU2004273053B2 (en) 2010-05-20
EP1664346A2 (en) 2006-06-07
HK1092841A1 (en) 2007-02-16
ATE480641T1 (de) 2010-09-15
IL174195A0 (en) 2006-08-01
AU2004273053A1 (en) 2005-03-24
AU2010212460A1 (en) 2010-09-09
CA2538514A1 (en) 2005-03-24
JP2007504825A (ja) 2007-03-08
KR20060083208A (ko) 2006-07-20
WO2005026392A3 (en) 2005-08-11
KR101081040B1 (ko) 2011-11-09
IL174195A (en) 2012-08-30
US8088730B2 (en) 2012-01-03
NZ546488A (en) 2009-01-31
US20070086997A1 (en) 2007-04-19
RU2420583C2 (ru) 2011-06-10
CN101023184A (zh) 2007-08-22
US20050059015A1 (en) 2005-03-17
IL200120A0 (en) 2011-08-01

Similar Documents

Publication Publication Date Title
IL200120A0 (en) Compositions, reagents and kits for and methods of diagnosing, monitoring and treating obesity and/or diabetes
ATE424560T1 (de) Marker für neuromyelitis optica
DE602006017365D1 (de) Zusammensetzungen für die identifizierung von adenoviren
NO20063624L (no) FC region varianter
WO2005111212A3 (en) Biological bar code
DK1316801T3 (da) Sammensætninger og fremgangsmåder til detektion og behandling af sygdomme og tilstande, som er relateret til kemokinreceptorer
SG169361A1 (en) Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
WO2004074455A3 (en) Fc REGION VARIANTS
WO2006131928A3 (en) Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis
WO2009083950A3 (en) Biomarkers for the prediction of renal injury
ATE504836T1 (de) Verfahren zur identifizierung von trpv2- modulatoren
WO2007134028A3 (en) Biomarkers for depression and methods using the same
TW200833842A (en) Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
WO2007047408A3 (en) Promac signature application
WO2003038444A3 (en) Biomarkers of liver function
WO2006069023A3 (en) Assay method and apparatus with reduced sample matrix effects
WO2003087761A3 (en) Molecular profiling of disease and therapeutic response using phospho-specific antibodies
WO2004070025A3 (en) Novel goodpasture antigen-binding protein isoforms and protein misfolded-mediated disorders
NO20064715L (no) Deteksjon, isolering og anvendelse av renalase (monoamin aksidase C)
WO2004070012A3 (en) Cell-killing molecules and methods of use thereof
SG146459A1 (en) Compositions, reagents and kits for and methods of diagnosing, monitoring and treating obesity and/or diabetes
NO20052553L (no) Cobalaminanalyse.
WO2005039573A3 (en) Biomarkers for the prediction of drug-induced diarrhoea
WO2007055996A3 (en) Compositions, reagents and kits for and methods of diagnosing, monitoring and treating hormonal imbalance
NO20033401D0 (no) Kjemiske forbindelser

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]